Alector, Inc. (ALEC) Stock Analysis
A live, multi-source view of Alector, Inc. (ALEC): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology · United States · 103 employees · alector.com
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Alector, Inc. (ALEC) last closed at $2.46 (the last completed close before that scan).
Technicals at the scan: RSI 59 (neutral territory), price +8.4% versus its 20-day average, 20-day versus 50-day average spread +19.5%, MACD histogram 0.01.
Sentiment inputs: StockTwits 83% bullish; analyst consensus score 50/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ALEC; corporate insiders filed 0 buys and 5 sells (3 distinct filers, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Grace Wong-Sarad (0B/3S), Neil Lindsay Berkley (0B/1S), Arnon Rosenthal (0B/1S). Who is trading what
RapidTradeView pick record
ALEC has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Alector, Inc. (ALEC) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ALEC.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.